Table 4.

Characteristics, treatment and outcomes of patients with metastatic testicular adult granulosa cell tumors

No.	Author (year)	Age, Side	Size (mm)	Clinical presentation	Local treatment	Initial site and onset of metastatic disease (months after first diagnosis)	First-line treatment of metastatic disease	Response to first-line treatment	Risk factors for metastatic disease	Follow-up (months after diagnosis)
1	Suppiah, A. (2005)	51, left	Missing	Testicular enlargement	Orchiectomy	Bone, 72	Resection	CR	None	NED (76)
2	Mohapatra, A. (2016)	57, left	47	Palpable mass, gynecomastia	Orchiectomy	RPLN, 0	RPLND	CR	Size + , gynecomastia + , angiolymphatic invasion+	NED (32)
3	Matoska, J. (1992)	26, left	100	Testicular enlargement, gynecomastia	Orchiectomy	RPLN, 0	RPLND, RT	CR	Size + , gynecomastia +, angiolymphatic invasion+	NED (168)
4	Elbachiri, M. (2017)	40, left	55	Palpable mass	Orchiectomy	RPLN, 0	Chemo (BEP)	CR	Size+	NED (6)
5	Hammerich, K. H. (2008)	55, right	105	Testicular enlargement	Orchiectomy	Lung, 0	Chemo (BEP)	CR	Size + , angiolymphatic invasion+	NED (13)
6	Jimenez-Quintero, L. P. (1993)	60, left	70	Testicular enlargement	Orchiectomy	RPLN, liver, 121	Chemo (DC)	PD	Size+	DOD (134)
7	Jimenez-Quintero, L. P. (1993)	29, right	75	Incidental	Orchiectomy	RPLN, 0, ILN 12	RPLND, Chemo (E)	PD: ILN met. (12 Mo) 2nd line: INLD, RT	Size + , angiolymphatic invasion+	SD (14)

RPLND retroperitoneal lymph node dissection, ILN inguinal lymph nodes, ILND inguinal lymph node dissection, RT radiotherapy, DOD died of disease, CR complete remission, PD progressive disease, NED no evidence of disease, SD stable disease, Chemo BEP: bleomycin, etoposide, cisplatin, DC doxorubicin–cisplatin, E etoposide